We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Alantos Pharmaceuticals Holding, a privately held biopharmaceutical company
focused on the discovery and development of small molecule drugs with a focus
on osteoarthritis/inflammation and Type II diabetes, announced it has raised
$20 million in a series B private round of financing from existing investors
Oxford Bioscience Partners, SV Life Sciences, Earlybird, ABN AMRO, Heidelberg
Innovation and Ventech. Proceeds from the financing will be used to progress
the company's pipeline of compounds, particularly its two lead candidates for
diabetes and osteoarthritis into clinical development.
Dutch biotechnology company Crucell N.V. and allied contract manufacturer DSM
Biologics announced that they have signed a PER.C6 research license agreement
with leading Japanese pharmaceutical company JCR Pharmaceuticals.
AXM Pharma announced that it entered into a distribution agreement with Sinopharm
Holding Guangzhou for an expected purchase amount through December 2005 of RMB
54,000,000 (US$6,560,000) for the company's line of Elegance products, formerly
known as Whisper.
Barr Pharmaceuticals has confirmed that Kos Pharmaceuticals has filed a motion
for a temporary restraining order and a preliminary injunction in the United
States District Court for the Southern District of New York seeking to prevent
Barr from launching generic versions of Kos' Niaspan 500-mg, 750-mg and 1,000-mg
extended-release tablets (Niacin extended-release tablets) following final U.S.
Food & Drug Administration (FDA) approval.
Callisto Pharmaceuticals, a biopharmaceutical company focused on the development
of drugs to treat cancer and osteolytic bone disease, announced the completion
of a private placement of approximately 1.99 million shares of its common stock
at a per share price of $1.52, for aggregate gross proceeds of approximately
$3.02 million.
Aspreva Pharmaceuticals Corp. has raised $113.3 million in its initial public
offering. The Victoria-based drug developer said it has closed its offering
of 8.28 million shares at a price of $13.68 per share.
ImaRx Therapeutics, a biopharmaceutical company developing
NanoInvasive therapies for stroke and cancer, has announced the placement of
2.3 million shares of common stock raising gross proceeds of $7 million.
The FDA has issued a health advisory on AstraZeneca's Crestor, announcing that
the cholesterol drug, like other statins, can have a rare side effect of serious
muscle damage.
The American public is growing increasingly doubtful of the FDA's ability to
ensure the safety of prescription drugs, according to a new national poll.